""""""""The focus of the CMBS is pediatric neuroectodermal tumors including neuroblastoma, brain tumors and Ewings sarcoma. Retinoic Acid(RA) induced differentiation of neuroblastoma tumor cell lines continues to be our model for studies that define the signal transduction paths that mediate growth control, differentiation and cell death. Using a series of receptor selective retinoids ligands we found that RAR and RXR nuclear receptors are required to mediate maximal growth inhibiting and differentiating effects of retinoids. The most active combinations were ligands that activated RARbeta;RXR heterodimers followed by ligands activiating RARalpha:RXR and RARgamma:RXR. We identified one agonist that was more potent than RA & 9cisRA in inhibiting growth and inducing differentiation, whether this compound has clinical utility remains to be evaluated. Differential display was utilized to identify genes that may be selectively activated by these agonists. Several candidate differentially displayed mRNA have been isolated, cloned and are under investigation. We have determined that the molecular mechanisms by which retionids causes a G1 arrest of cell growth in NB cells is via a complete inhibition of G1 cyclin-dependent kinases. The decrease in kinase activity is caused by an increase in p27kip and its binding to G1 cyclin-dependent kinases. As the increase in p27 is not transcriptionally regulated, it may be due to the RA induced decrease in N-myc which leads to a desequestration of p27. The expression of G1 cyclins and cdks and other inhibitors are unchanged during RA treatment. In NB tumors, Trks serve as tumor markers; TrkA is expressed in good prognosis tumors and most poor prognosis tumor express TrkB. We have found that the differential activation of these signal transduction pathways in NB may alter their growth, invasiveness, chemosensitivity and cell survival. Using tet-regulated expression vectors we have made a series of NB cells which express varying levels of Trk and are testing the effects of activation of these paths on cell growth. We find that NGF treatment of cells expressing high levels of TrkA causes a marked decrease in cell number by delaying but not arresting progression through the cell cycle. This is associated with decreases in N-myc and increases in p27 binding to cdk-kinases. Thus using RA or NGF we find decreases in N-myc and increases in p27 associated with growth inhibition.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC006813-16
Application #
6123685
Study Section
Physical Biochemistry Study Section (PB)
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Li, Z; Zhang, J; Liu, Z et al. (2007) Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 14:318-26
McKee, Amy E; Thiele, Carol J (2006) Targeting caspase 8 to reduce the formation of metastases in neuroblastoma. Expert Opin Ther Targets 10:703-8
Nakamura, Katsuya; Martin, Kelly C; Jackson, Jennifer K et al. (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66:4249-55
Liu, Zhihui; Yang, Xuezhong; Tan, Fei et al. (2006) Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation. Biochem Biophys Res Commun 344:834-44
Choi, Yoon-La; Kim, Chong Jai; Matsuo, Tatsuya et al. (2005) HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J Neurooncol 73:19-27
Lavoie, Jean-Francois; Lesauteur, Lynne; Kohn, Judi et al. (2005) TrkA induces apoptosis of neuroblastoma cells and does so via a p53-dependent mechanism. J Biol Chem 280:29199-207
Li, Zhijie; Jaboin, Jerry; Dennis, Phillip A et al. (2005) Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res 65:2070-5
Beppu, Kiichiro; Nakamura, Katsuya; Linehan, W Marston et al. (2005) Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65:4775-81
Barenboim-Stapleton, Linda; Yang, Xuezhong; Tsokos, Maria et al. (2005) Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line. Cancer Genet Cytogenet 157:109-17